CBTN and Day One Join Forces to Innovate Pediatric Brain Tumor Treatments

CBTN and Day One Collaboration

The Children's Brain Tumor Network (CBTN) has established a pioneering partnership with Day One Biopharmaceuticals, a company focused on creating targeted treatments for serious conditions in people of all ages. This collaboration seeks to enhance the design and implementation of clinical trials aimed at treating children suffering from brain tumors. By drawing on the rich resources of the Pediatric Brain Tumor Atlas (PBTA), a comprehensive data repository encompassing genomic, clinical, and imaging information from over 7,600 pediatric brain tumor patients, the two organizations are poised to make significant strides in therapy development.

Dr. Angela Waanders, the LLG Study Chair for the Children's Brain Tumor Network, expressed gratitude for the collaborative effort, citing a shared dedication to improving treatment outcomes for affected children globally. She emphasized the vital role that joining CBTN's extensive resources with Day One's innovative strategies plays in hastening the progress of clinical trials designed specifically for young patients.

The partnership is designed not only to foster innovation in clinical trial design but also to ensure that valuable data remains accessible to the wider scientific community. This commitment to open data supports collaborative efforts with commercial entities, enabling advancements that could lead to new therapeutic options.

Dr. Elly Barry, Chief Medical Officer at Day One, pointed out that CBTN's dedication to transparency and their unrivaled expertise in pediatric brain tumors positions them as an optimal partner. The collaboration aims to enhance the design of clinical trials, potentially paving the way for new treatment avenues for children in critical need of effective therapies.

Moreover, the CBTN and Day One partnership opens the door for creating external control arms in clinical studies for children, ultimately enhancing the reliability and relevance of the trial results.

About Children’s Brain Tumor Network

CBTN represents a collective research initiative dedicated to ensuring no child experiences the devastating effects of brain tumors. With a network of 35 international institutions, CBTN has successfully enrolled over 7,000 participants and amassed more than 70,000 biospecimen samples, forming one of the most comprehensive databases for childhood brain tumors worldwide. This wealth of data fuels research efforts aimed at discovering more effective treatment strategies.

As the partnership between CBTN and Day One unfolds, the promise of new, targeted therapies continues to grow, igniting hope for countless families affected by pediatric brain tumors. For more information about CBTN and their ongoing commitment to brain tumor research, visit cbtn.org.